IDEXX Laboratories (FRA:IX1) EBIT: €1,211 Mil (TTM As of Mar. 2026)


FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €473.80
GF Value €552.99
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories EBIT?

IDEXX Laboratories FRA:IX1 -0.19% 96 EBIT is €1,211 Mil as of Mar. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €552.99 (Modestly Undervalued).

IDEXX Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €314 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €1,211 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. IDEXX Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 40.92%. IDEXX Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 106.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. IDEXX Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.12%.


IDEXX Laboratories  (FRA:IX1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

IDEXX Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1254.548 * ( 1 - 21.66% )/( (2365.282 + 2438.624)/ 2 )
=982.8129032/2401.953
=40.92 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2861.548 - 342.486 - ( 153.78 - max(0, 981.087 - 1207.408+153.78))
=2365.282

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2928.455 - 356.427 - ( 173.457 - max(0, 1124.371 - 1257.775+173.457))
=2438.624

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

IDEXX Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1256.612/( ( (743.499 + max(379.346, 0)) + (745.437 + max(490.35, 0)) )/ 2 )
=1256.612/( ( 1122.845 + 1235.787 )/ 2 )
=1256.612/1179.316
=106.55 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(471.731 + 322.604 + 139.039) - (342.486 + 30.115 + 181.427)
=379.346

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(522.066 + 330.776 + 150.454) - (356.427 + 31.424 + 125.095)
=490.35

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

IDEXX Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1210.978/38865.517
=3.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEXX Laboratories EBIT Related Terms


IDEXX Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories EBIT Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 825.23 849.44 1,011.23 1,089.69 1,164.04

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.92 323.97 302.82 270.03 314.15

FRA:IX1 vs A, WAT, NTRA: EBIT Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's EV-to-EBIT falls into.


FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,211 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €1,211 Mil mean?
IDEXX Laboratories (FRA:IX1) has a EBIT of €1,211 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IDEXX Laboratories.
Is IDEXX Laboratories' EBIT too high?
IDEXX Laboratories' current EBIT is €1,211 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EBIT compare to A and WAT?
IDEXX Laboratories' EBIT of €1,211 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on IDEXX Laboratories. IDEXX Laboratories's current EBIT is €1,211 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €552.99, compared to a current price of €473.80 — trading 14.3% below its estimated fair value. The current EBIT is €1,211 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EBIT is €1,211 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €473.80 is trading 14.3% below its estimated GF Value™ of €552.99. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:IX1:

  • EBIT: €1,211 Mil
  • GF Value™: €552.99 vs. price of €473.80 (14.3% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€473.80
Price
€552.99
GF Value